Zobrazeno 71 - 80
of 100
pro vyhledávání: '"G. Caleb Alexander"'
Autor:
Sheriza N Baksh, Jodi B Segal, Mara McAdams-DeMarco, Rita R Kalyani, G Caleb Alexander, Stephan Ehrhardt
Publikováno v:
PLoS ONE, Vol 15, Iss 10, p e0240141 (2020)
BackgroundCardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) in patients without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 diabetes often excluded from clinical trials on this association, i
Externí odkaz:
https://doaj.org/article/27a77af8103d4a7e99b211fe73192937
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234065 (2020)
BackgroundThe association between sodium-glucose cotransporter 2 inhibitors (SGLT2i's) and lower extremity amputation is unclear.PurposeTo systematically review randomized control trials (RCTs) and observational studies quantifying risk of lower extr
Externí odkaz:
https://doaj.org/article/cd85e32ccb90450989ebdbd3f3b69224
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0225109 (2019)
Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakehold
Externí odkaz:
https://doaj.org/article/1e91ec8cbda3424db9a0cab0ea3098b2
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0211820 (2019)
BackgroundClinical guidelines recommend that metformin be continued after insulin is initiated among patients with type 2 diabetes, yet little is known regarding how often metformin or other non-insulin diabetes medications are continued in this sett
Externí odkaz:
https://doaj.org/article/7ee505515a1249dc893ac397e89f19c0
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195012 (2018)
For nearly a century, no generic form of insulin has been available in the United States. However, the first biosimilar insulin, Basaglar, was approved by the U.S. Food and Drug Administration in 2015, and subsequently Admelog and Lusduna in 2017.To
Externí odkaz:
https://doaj.org/article/29fcfdec75334fcea4de1953ab26c53b
Autor:
Dima Mazen Qato, Shannon Zenk, Jocelyn Wilder, Rachel Harrington, Darrell Gaskin, G Caleb Alexander
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183172 (2017)
IMPORTANCE:Despite their increasingly important role in health care delivery, little is known about the availability, and characteristics, of community pharmacies in the United States. OBJECTIVES:(1) To examine trends in the availability of community
Externí odkaz:
https://doaj.org/article/04ce35562d134a9b8546c953c1ff3574
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119292 (2015)
ImportanceHypertension is common and costly. Over the past decade, new antihypertensive therapies have been developed, several have lost patent protection and additional evidence regarding the safety and effectiveness of these agents has accrued.Obje
Externí odkaz:
https://doaj.org/article/57656a1479144173b74ab86c08d28a58